XML 39 R24.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Quarterly Financial Information (Unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract] |
Quarterly Financial Information (Unaudited) | Quarterly Financial Information (Unaudited) The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2015 and 2014 (unaudited):
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2015 |  | September 30, 2015 |  | June 30, 2015 |  | March 31, 2015
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenue: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 1,820,643 |  |  | $ | 16,475,083 |  |  | $ | 4,335,236 |  |  | $ | 4,245,571 |
Revenue under collaborative research and development arrangements with affiliated entity | 375,000 |  |  | 125,000 |  |  | 166,667 |  |  | 112,500 |
Grants and miscellaneous revenue | 3,739,919 |  |  | 7,583,151 |  |  | 784,775 |  |  | 808,566 |
Total revenues | 5,935,562 |  |  | 24,183,234 |  |  | 5,286,678 |  |  | 5,166,637 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 15,601,891 |  |  | 16,075,201 |  |  | 16,688,511 |  |  | 9,426,320 |
General and administrative | 4,860,086 |  |  | 4,377,616 |  |  | 4,718,260 |  |  | 4,107,928 |
Gain on sale of assets | — |  |  | — |  |  | (1,000,000 | ) |  | — |
Total operating expenses | 20,461,977 |  |  | 20,452,817 |  |  | 20,406,771 |  |  | 13,534,248 |
Income (Loss) from operations | (14,526,415 | ) |  | 3,730,417 |  |  | (15,120,093 | ) |  | (8,367,611 | )
Interest and other income, net | (194,519 | ) |  | 214,982 |  |  | 146,332 |  |  | 138,276 |
Change in fair value of common stock warrants | (290,316 | ) |  | 518,877 |  |  | (49,773 | ) |  | (1,227 | )
Gain (Loss) from investment in affiliated entity | (3,249,315 | ) |  | (659,054 | ) |  | 8,861,145 |  |  | (2,352,309 | )
Net income (loss) before income tax benefit | (18,260,565 | ) |  | 3,805,222 |  |  | (6,162,389 | ) |  | (10,582,871 | )
Income tax benefit | 308,520 |  |  | 1,789,246 |  |  | — |  |  | — |
Net income (loss) | (17,952,045 | ) |  | 5,594,468 |  |  | (6,162,389 | ) |  | (10,582,871 | )
Net (income) loss attributable to non-controlling interest | — |  |  | — |  |  | (85,861 | ) |  | 1,092 |
Net income (loss) attributable to Inovio Pharmaceuticals, Inc. | $ | (17,952,045 | ) |  | $ | 5,594,468 |  |  | $ | (6,248,250 | ) |  | $ | (10,581,779 | )
Net income (loss) per common share attributable to Inovio Pharmaceuticals, Inc. stockholders |  |  |  |  |  |  |
Basic | $ | (0.25 | ) |  | $ | 0.08 |  |  | $ | (0.09 | ) |  | $ | (0.17 | )
Diluted | $ | (0.25 | ) |  | $ | 0.07 |  |  | $ | (0.09 | ) |  | $ | (0.18 | )
Weighted average number of common shares outstanding used in per share calculations: |  |  |  |  |  |  |
Basic | 72,194,504 |  |  | 72,029,644 |  |  | 67,655,975 |  |  | 60,741,082 |
Diluted | 72,194,504 |  |  | 73,961,237 |  |  | 67,838,738 |  |  | 60,913,423 |
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2014 |  | September 30, 2014 |  | June 30, 2014 |  | March 31, 2014
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenue: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 1,758,108 |  |  | $ | 1,114,952 |  |  | $ | 3,107,781 |  |  | $ | 1,435,727 |
Revenue under collaborative research and development arrangements with affiliated entity | 112,500 |  |  | 112,500 |  |  | 137,500 |  |  | 116,964 |
Grants and miscellaneous revenue | 586,500 |  |  | 612,901 |  |  | 556,381 |  |  | 804,952 |
Total revenues | 2,457,108 |  |  | 1,840,353 |  |  | 3,801,662 |  |  | 2,357,643 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 9,244,473 |  |  | 7,017,805 |  |  | 9,607,281 |  |  | 8,225,480 |
General and administrative | 4,224,429 |  |  | 3,153,714 |  |  | 4,347,327 |  |  | 4,132,218 |
Total operating expenses | 13,468,902 |  |  | 10,171,519 |  |  | 13,954,608 |  |  | 12,357,698 |
Loss from operations | (11,011,794 | ) |  | (8,331,166 | ) |  | (10,152,946 | ) |  | (10,000,055 | )
Interest and other income, net | 113,212 |  |  | 97,174 |  |  | 68,999 |  |  | 52,076 |
Change in fair value of common stock warrants | 143,659 |  |  | (113,980 | ) |  | 824,390 |  |  | (505,926 | )
Gain (Loss) from investment in affiliated entity | 3,342,436 |  |  | 1,168,911 |  |  | (1,458,160 | ) |  | (376,963 | )
Net loss | (7,412,487 | ) |  | (7,179,061 | ) |  | (10,717,717 | ) |  | (10,830,868 | )
Net loss attributable to non-controlling interest | 1,083 |  |  | 1,486 |  |  | 6,443 |  |  | 9,408 |
Net loss attributable to Inovio Pharmaceuticals, Inc. | $ | (7,411,404 | ) |  | $ | (7,177,575 | ) |  | $ | (10,711,274 | ) |  | $ | (10,821,460 | )
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders |  |  |  |  |  |  |
Basic | $ | (0.12 | ) |  | $ | (0.12 | ) |  | $ | (0.18 | ) |  | $ | (0.20 | )
Diluted | $ | (0.12 | ) |  | $ | (0.12 | ) |  | $ | (0.19 | ) |  | $ | (0.20 | )
Weighted average number of common shares outstanding used in per share calculations: |  |  |  |  |  |  |
Basic | 60,610,367 |  |  | 60,392,911 |  |  | 60,232,498 |  |  | 55,159,002 |
Diluted | 60,805,871 |  |  | 60,602,831 |  |  | 60,474,859 |  |  | 55,159,002 |

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a)-(j) -URI http://asc.fasb.org/extlink&oid=35737889&loc=d3e1280-108306 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section G -Subsection 1 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K (SK) -Number 229 -Section 302 -Paragraph a + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration